Brightworth Bristol Myers Squibb CO Transaction History

Brightworth

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$61.48 - $73.72 $706,220 - $846,821	-11,487 Closed	0 $0
Q4 2021 Jan 26, 2022	BUY	$53.63 - $62.52 $122,919 - $143,295	2,292 Added 24.93%	11,487 $716,000
Q3 2021 Oct 27, 2021	BUY	$59.17 - $69.31 $27,987 - $32,783	473 Added 5.42%	9,195 $544,000
Q2 2021 Jul 29, 2021	BUY	$61.91 - $67.42 $8,172 - $8,899	132 Added 1.54%	8,722 $583,000
Q1 2021 Apr 19, 2021	BUY	$59.34 - $66.74 $63,968 - $71,945	1,078 Added 14.35%	8,590 $542,000
Q4 2020 Feb 03, 2021	BUY	$57.74 - $65.43 $82,452 - $93,434	1,428 Added 23.47%	7,512 $466,000
Q3 2020 Nov 02, 2020	BUY	$57.43 - $63.64 $80,631 - $89,350	1,404 Added 30.0%	6,084 $367,000
Q2 2020 Jul 22, 2020	BUY	$54.82 - $64.09 $256,557 - $299,941	4,680 New	4,680 $275,000
Q2 2018 Aug 03, 2018	SELL	$50.53 - $62.98 $173,115 - $215,769	-3,426 Closed	0 $0
Q1 2018 Apr 25, 2018	SELL	$59.92 - $68.98 $9,527 - $10,967	-159 Reduced 4.44%	3,426 $217,000
Q4 2017 Jan 24, 2018	SELL	$59.94 - $65.35 $4,015 - $4,378	-67 Reduced 1.83%	3,585 $220,000
Q3 2017 Oct 30, 2017	BUY	$55.23 - $63.74 $201,699 - $232,778	3,652	3,652 $233,000

2,533

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $120B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Brightworth, based on Form 13F filings with the SEC.

Stay updated on Brightworth with notifications on news.